Seedlabs

Post-Infusion Cisplatin Adduct Blood Test for Cycle Dose Tuning

A blood test that tells oncologists how much DNA damage a chemo dose caused so they can adjust the next dose.

A lab test that measures cisplatin-DNA adducts in a patient's white blood cells right after infusion and again 24 hours later, telling the oncologist how much DNA damage the dose actually caused and how fast the patient clears it, so later cycles can be dosed up or down with evidence.

MedicineChemotherapy-induced organ toxicity mitigation
Metabolism and Genetic DisordersOncology clinical diagnostics - pharmacodynamic monitoring of cisplatin chemotherapy dosing

Concept

A lab-developed test run on two ordinary blood draws from a cisplatin patient: one shortly after the infusion, one 24 hours later. DNA is isolated from peripheral leukocytes and the dominant cisplatin lesion - the pGpG intrastrand cross-link - is quantified at fmol levels with adduct-specific antisera, exactly as demonstrated in the source study. The report returns two numbers per cycle: peak adduct burden (how much DNA damage this dose actually produced in this patient) and percent removed at 24 h (how fast the patient clears it). The single wedge is first-cycle probing of dose adequacy: patients who form few adducts are candidates for escalation in later cycles, patients who form many are candidates for de-escalation or added supportive care. Because the source study is a 7-patient, first-dose demonstration, the product is sized as a send-out assay at a specialized oncology reference lab with a prospective validation study against toxicity and response as phase one - not a point-of-care device.

Why now

The paper establishes, for the first time in patients, that all four cisplatin-DNA products known from in vitro chemistry appear in leukocyte DNA after a single in vivo dose in stable proportions (65% pGpG intrastrand cross-links, 22% pApG, 13% interstrand/non-adjacent-guanine cross-links, under 1% monofunctional guanine adducts), and that newly raised antisera detect them at fmol levels from routine blood samples. It further documents 'strong individually determined differences' in adduct formation across six first-treatment patients and that 'a substantial part of the adducts is removed within the first 24 h' - so both an exposure signal and a clearance signal are available from two standard draws in time to adjust the next cycle. Cisplatin remains a generic backbone across bladder, ovarian, head-and-neck and lung cancer, still dosed by body-surface-area convention with no pharmacodynamic feedback; this assay supplies that missing feedback loop.

Written by GLM · 3 Oct 2026

AI assessment

Backed by 1 paper86

A high-precision pharmacodynamic assay that transforms cisplatin dosing from a generic BSA-based guess to a personalized, evidence-based regimen using leukocyte DNA adducts.

Evidence strength
4/5
The research explicitly demonstrates the ability to quantify specific adducts at fmol levels in human patients and identifies significant inter-patient variability in both formation and clearance.
Market pull
4/5
Cisplatin is a foundational chemotherapy for multiple major cancers, and oncologists have a high urgency to reduce toxicity and improve efficacy through precise dosing.
Novelty & moat
5/5
Unlike the listed ideas which focus on environmental lead or tumor mutations (ctDNA), this targets the direct pharmacodynamic effect of the drug on the patient's own DNA.
Feasibility
3/5
While the lab method is proven, scaling it as a clinical 'send-out' assay requires rigorous validation against clinical outcomes (toxicity/response) and regulatory approval.
Wedge clarity
5/5
The focus on first-cycle probing to determine dose escalation or de-escalation is a sharp, actionable clinical entry point.
Simplicity / focus
5/5
The product is a single, focused diagnostic test with a clear input (two blood draws) and a clear output (two metrics for dose tuning).

Scored by Gemma 4 · 3 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • The University of Texas MD Anderson Cancer Centerorganization

    Treats large volumes of cisplatin patients in head-and-neck and gynecologic oncology; an adduct-based dose feedback test directly supports its dose-personalization and toxicity-reduction programs.

  • Mayo Clinicorganization

    Through Mayo Clinic Laboratories it both validates and distributes novel oncology tests; the two-draw reference-lab workflow fits its outreach model.

  • LabCorpcompany

    Operates national oncology send-out testing; a validated leukocyte-adduct LDT would be a new billable test in the large cisplatin-treated population.

  • The US Oncology Networkcompany

    Community practices delivering chemotherapy at scale; a simple measured dose-feedback test aligns with its value-based care and toxicity-management focus.

Research it builds on

  1. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
    A M Fichtinger-Schepman, A T van Oosterom, Paul H.M. Lohman et al. · 2026 · 265 citations
    All ideas from this paper →
Leave feedback
feasibility